Everest Organics Limited today announced the successful development of an anti-viral API ‘MOLNUPIRAVIR’ an additional COVID-19 treatment drug that is being developed at Lab Scale for the first-line treatment of COVID-19 in adults patients with mild to moderate symptoms.
Dr. Srikakarlapudi Sirisha, Chief Executive Officer, EOL – New Product Development said that “After the successful development and commercialization of various COVID-19 drugs, such as Oseltamivir, Remdesivir, Posaconazole, Everest Organics Limited is on its path of expansion of this portfolio and hence has further developed an additional COVID-19 treatment API in that segment. ‘Molnupiravir’ is an API that reduces the risk of hospitalization and death by around 50% for patients with mild or moderate cases of Covid. The APl, Molnupiravir is administered orally and works by inhibiting the replication of the coronavirus inside the body. Everest is planning and preparing to be an active player in viral segment in the upcoming future.
You may also like
-
Indian Pharma Giants Commit $19.1 Billion to US Expansion, Signalling a New Phase in Global Growth
-
Researchers Launch BHARAT Study to Build India’s First Large-Scale Ageing Biomarker Database
-
Why Indian Kitchen Spices Were Actually Ancient Preventive Medicine Systems
-
India’s Genome Is Not Western: GenomeIndia Study Calls for India-Specific Precision Medicine
-
CDSCO Tightens Drug Safety Reporting Rules, Asks Firms to File PSURs From Actual Launch Date
